| 标题： | 生物制剂在系统性红斑狼疮中应用的中国专家共识 |
| title： | Chinese expert consensus on the use of biologics in systemic lupus erythematosus |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 治疗 |
| field： | Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | Clinicians at all levels (rheumatology and other related fields) |
| Guide users： | 各级临床医生（风湿病和其他相关领域） |
| 证据分级方法： | GRADE 分级系统 |
| Evidence grading method： | Grading of recommendations assessment, development and evaluation system |
| 制定单位： | 中国初级卫生保健基金会，中华医学会风湿病学分会 |
| Formulating unit： | Chinese Primary Health Care Foundation, Chinese Rheumatology Association |
| 注册时间： | 2023-07-24 |
| Registration time： | |
| 注册编号： | PREPARE-2023CN532 |
| Registration number： | |
| 指南制订的目的： | 本共识主要聚焦国内临床用于治疗系统性红斑狼疮的生物制剂，收集汇总相关临床证据，并结合SLE诊疗的指南以及我国临床专家的实践经验，对生物制剂的适用人群、使用时机、疗效评估、安全用药等关键问题提出推荐意见，为临床医师应用生物制剂治疗SLE提供参考，推动生物制剂在临床中的规范合理应用。 |
| Purpose of the guideline： | This expert consensus focused on the biologics used in systemic lupus erythematosus (SLE) in China. Based on clinical evidence, current guidelines and experts' opinion, this consensus provided physicians with up-to-date guidance on the appropriate use of biologics in the management of SLE, with detailed information in how to choose the target population for biologics, the timing of using biologics as well as the assessment of the efficacy and safety. Our objective was to promote the standardised use of biologics in the management of SLE. |
